- The U.S. on Oct. 28 purchased 50 million more doses of Pfizer’s COVID-19 vaccine to prepare for pediatric vaccinations.
- The U.S. on Nov. 9 purchased 1.4 million more courses of molnupiravir, the COVID-19 antiviral pill Merck is developing with Ridgeback Biotherapeutics, for roughly $1 billion. The U.S. has now committed to purchase a total of 3.1 million courses of the antiviral for about $2.2 billion.
- The U.S. said Nov. 16 it will buy 10 million courses of Pfizer’s COVID-19 antiviral pill Paxlovid for $5 billion.
- The U.S. on Nov. 17 bought $1 billion worth of COVID-19 monoclonal antibody drug sotrovimab, which is made by GlaxoSmithKline and Vir Biotechnology.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
